Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.

Muskiet, M H A; Tonneijck, L; Smits, M M; Kramer, M H H; Diamant, M; Joles, J A; van Raalte, D H

Muskiet, M H A; Tonneijck, L; Smits, M M; Kramer, M H H; Diamant, M; Joles, J A; van Raalte, D H.

Affiliation

Muskiet MH; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Tonneijck L; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Smits MM; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Kramer MH; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Diamant M; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.
Joles JA; Department of Nephrology and Hypertension, University Medical Centre, Utrecht, The Netherlands.
van Raalte DH; Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, Amsterdam, The Netherlands.

Diabetes Obes Metab ; 18(2): 178-85, 2016 Feb.

Article in En | MEDLINE | ID: mdl-26636423

Subject(s)
Key words

GLP1 receptor agonist; LNMMA; exenatide; nitric oxide; renal haemodynamics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peptides / Vascular Resistance / Venoms / Nitric Oxide Synthase / Overweight / Glucagon-Like Peptide-1 Receptor / Hypoglycemic Agents / Kidney Type of study: Clinical_trials Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2016 Document type: Article Affiliation country: Países Bajos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google